Volume : 09, Issue : 06, June – 2022
11.FORMULATION AND EVALUATION OF COLON TARGETING MICROSPHERES CONTAINING SULFASALAZINE FOR IBD
Ashi Jain*, Mrs. Mahak Jain, Ankur Singhai, Aayushi Patel, Prabhat Kumar Jain, Dr. Sunil Kumar Jain
The main objective of the work was to prepare and evaluate sulfasalazine loaded microspheres for sustained delivery for the treatment of inflammatory bowel disease. Sulfasalazine has crystalluria, thrombocytopenia, and megaloblastic anemia as side effects, so to reduce side effect microspheres were prepared. The sulfasalazine microspheres were prepared by inotropic gelation method by optimizing process parameters such as concentration of calcium chloride, agitation speed, and time of agitation. The concentration of polymer sodium alginate was varied. Among the all formulations, the best formulation was considered by comparing process parameters such as the entrapment efficiency, drug content, in vitro drug release studies, scanning electron microscope analysis, and zeta potential. The prepared microspheres were stable, spherical particles and showed favorable release profiles in simulated colonic fluid. However, additional evaluation of these carriers can be performed for their probableto treat colonic diseases, as a future scope.
Key words:Sulfasalazine, Microspheres, Inflammatory bowel disease, Development, Characterization
Cite This Article:
Please cite this article in pressAshi Jainet al,Formulation And Evaluation Of Colon Targeting Microspheres Containing Sulfasalazine For Ibd.,Indo Am. J. P. Sci, 2022; 09(6).,
Number of Downloads : 10
1. Sohrabpour AA, Malekzadeh R, Keshavarzian A. Current therapeutic approaches in inflammatory bowel disease. Curr Pharm Des 2010; 16:3668-83.
2. G. Guariso, M. Gasparetto, L. Visona Dalla Pozza et al., “Inflammatory bowel disease developing in paediatric and adult age,” Journal of Pediatric Gastroenterology and Nutrition, vol. 51, no. 6, pp. 698–707, 2010.
3. M. W. Laass, D. Roggenbuck, and K. Conrad, “Diagnosis and classification of Crohn’s disease”, Autoimmunity Reviews, vol. 13, no. 4-5, pp. 467–471, 2014.
4. M. S. Silverberg, J. Satsangi, T. Ahmad et al., “Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology,” CanadianJournal of Gastroenterology, vol. 19, supplement A, pp. 5A–36A, 2005.
5. L. M. Spekhorst, M. C. Visschedijk, R. Alberts et al., “Performance of the Montreal classification for inflammatory bowel diseases,” World Journal of Gastroenterology, vol. 20, pp. 15374– 15381, 2014.
6. Chein YW. Oral Drug Delivery Systems: In Novel drug delivery systems. Vol.50, Marcel Dekker, Inc., New York. 1992, 139- 177.
7. P. Calvo, C. R. Lopez, J. Jato, and M. J. Alon, Hydrophilic chitosan polyethylene oxide nanoparticles as protein carriers. J. Appl. Polym. Sci. 63, 125 (1997).
8. K. Kim, S. J. Hwang, J. B. Park, and H. J. Park, Preparation and characterization of drug-loaded polymethacrylate microspheres by an emulsion solvent evaporation method. J. Microencap. 19, 811 (2002)
9. Chaurasia, M.; Chourasia, M.; Jain, N.K.; Jain, A.; Soni, V.; Gupta, Y.; Jain, S. Methotrexate bearing calcium pectinate microspheres: A platform to achieve colon-specific drug release. Curr. Drug Deliv. 2008, 5, 215–219.